Dr. Zhaohui Feng received his MD and PhD from Zhejiang University School of
Medicine and completed his postdoctoral training at NYU Medical School focusing
on DNA damage and repair before he moved to the University of Medicine and
Dentistry of New Jersey continuing his postdoctoral training with Dr. Arnold
Levine focusing on tumor suppressor p53. Since 2008, Dr. Feng has been a
faculty member at Rutgers Cancer Institute. He is a tenured Professor in the
Department of Radiation Oncology of Rutgers Cancer Institute at Rutgers
University. A major research interest of his group is to study the function and
mechanism of tumor suppressor p53. His
group discovered that p53 regulates metabolism through the regulation of AKT/mTOR signaling
pathways, and p53 targets genes, such as GLS2, Parkin, and RRAD. His group identified new mechanisms and
regulators for p53 regulation, including miR504, TRIM32, and LIF. His group's work also made important
contributions toward understanding the mechanisms underlying mutant p53 gain of oncogenic
activity in tumors, including promoting glycolysis through activation of
RhoA/Rock signaling. In addition, he studies the role and mechanism of
metabolic reprogramming in cancer and how metabolic reprogramming in cancer can
be targeted for therapy.
Dr. Zhaohui Feng received his MD and PhD from Zhejiang University School of
Medicine and completed his postdoctoral training at NYU Medical School focusing
on DNA damage and repair before he moved to the University of Medicine and
Dentistry of New Jersey continuing his postdoctoral training with Dr. Arnold
Levine focusing on tumor suppressor p53. Since 2008, Dr. Feng has been a
faculty member at Rutgers Cancer Institute. He is a tenured Professor in the
Department of Radiation Oncology of Rutgers Cancer Institute at Rutgers
University. A major research interest of his group is to study the function and
mechanism of tumor suppressor p53. His
group discovered that p53 regulates metabolism through the regulation of AKT/mTOR signaling
pathways, and p53 targets genes, such as GLS2, Parkin, and RRAD. His group identified new mechanisms and
regulators for p53 regulation, including miR504, TRIM32, and LIF. His group's work also made important
contributions toward understanding the mechanisms underlying mutant p53 gain of oncogenic
activity in tumors, including promoting glycolysis through activation of
RhoA/Rock signaling. In addition, he studies the role and mechanism of
metabolic reprogramming in cancer and how metabolic reprogramming in cancer can
be targeted for therapy.